ÂÜŔňÂŇÂ×

Dr. Love joined Global Blood Therapeutics (GBT) in June 2014 and currently serves as President and Chief Executive Officer and is also a member of the Board. Previously, he was executive vice president, research and development and technical operations, at Onyx Pharmaceuticals, Inc. Prior to Onyx, Dr. Love served as President, Chief Executive Officer, and Chairman of Nuvelo, Inc. Prior to Nuvelo, he served as Senior Vice President, Development, at Theravance, Inc. Earlier in his career, Dr. Love held a number of senior management positions in medical affairs and product development at Genentech, including as chairman of Genentech’s Product Development Committee and Vice President, Product Development. At Genentech, Dr. Love oversaw the development strategy and execution resulting in approvals of leading therapies such as Rituxan®, Herceptin®, Xolair®, and Avastin®. In addition to the Royalty Pharma and GBT Boards, he currently serves on the boards of directors of Amicus Therapeutics, Inc., and the Biotechnology Innovation Organization (BIO). Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.